More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

The talks on drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...

Novo specifically requested semaglutide be added to the FDA’s Demonstrable Difficulties for Compounding lists, citing complexities around formulations, delivery mechanisms, dosage forms ...

I found that so many people were making their own GLP-1s and taking smaller amounts than normally prescribed,” she said. “I thought since it's a smaller amount than what a doctor was giving out, it ...

Tirzepatide and semaglutide both belong to a class of drugs known as GLP-1s. Compounding pharmacies have been producing copycat versions of the drugs while they have been in short supply.

With tirzepatide and its Novo Nordisk rival semaglutide facing extended ... Late last month, Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said in a statement that the FDA decision ...